• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Penumbra Inc.

    5/30/25 4:20:01 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email
    SD 1 penformsd2024.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM SD
    SPECIALIZED DISCLOSURE REPORT
     
     
    PENUMBRA, INC.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 001-37557 05-0605598
    (State or other jurisdiction
    of incorporation)
     (Commission
    File Number)
     (I.R.S. Employer
    Identification No.)
     
    One Penumbra Place, Alameda, California 94502
    (Address of principal executive offices) (Zip Code)
    Johanna Roberts
    Executive Vice President, General Counsel and Secretary
    (510) 748-3200
    (Name and telephone number, including area code, of the person to contact in connection with this report)
     
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
     
    x

    Rule 13p-1 under the Securities Exchange Act (17 CFR 230.13p-1) for the reporting period from January 1 to December 31, 2024.






    Introduction

    This Specialized Disclosure Report on Form SD (this “Form SD”) of Penumbra, Inc. (“Penumbra,” the “Company,” “we,” or “us”) for the year ended December 31, 2024 is being filed to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”).

    Penumbra, headquartered in Alameda, California, is the world’s leading thrombectomy company and is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. Some of our products contain small amounts of tin, tungsten, and/or gold that are necessary to the functionality or production of those products. Substantially all of our products are manufactured at our manufacturing facilities in Alameda and Roseville, California. Penumbra does not purchase ore or unrefined tin, tungsten or gold from mines and instead relies on a small number of suppliers that provide us with materials containing these minerals. We rely on these suppliers to assist us with our reasonable country of origin inquiry regarding the minerals contained in the materials that they supply to us.

    Item 1.01. Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure

    Penumbra has evaluated its products that were manufactured during the calendar year ended December 31, 2024 (the “Reporting Period”), and has determined that certain of such products contain “conflict minerals,” which, for purposes of this Form SD, means columbite-tantalite, also known as coltan (the metal ore from which tantalum is extracted); cassiterite (the metal ore from which tin is extracted); gold; wolframite (the metal ore from which tungsten is extracted); and their derivatives (collectively, “3TG Minerals”). Specifically, certain of Penumbra’s thrombectomy, embolization and access, and immersive healthcare products contain tin, tungsten, and/or gold. These 3TG Minerals are necessary for the functionality or production of these products.

    The Company has identified ten suppliers (the “3TG Suppliers”) that supplied materials containing 3TG Minerals that were used in Penumbra products whose manufacture was completed during the Reporting Period (the “Products”).

    The Company conducted a reasonable country of origin inquiry (“RCOI”) on the 3TG Suppliers to determine whether the 3TG Minerals used in the Products originated in the Democratic Republic of the Congo or an adjoining country (collectively, the “Covered Countries”). The RCOI involved the following steps:

    •Penumbra requested from each 3TG Supplier a copy of the 3TG Supplier’s conflict minerals statement and/or policy, or any other declarations relating to their sourcing of 3TG Minerals;

    •Penumbra requested and received from each 3TG Supplier a completed Electronic Industry Citizenship Coalition (EICC) and the Global e-Sustainability Initiative (GeSI) Conflict Minerals Reporting Template (each, a “CMRT”), which asks the 3TG Supplier to disclose specified information regarding the inclusion of 3TG Minerals in their materials, including materials supplied to the Company, and the country of origin thereof. Each CMRT was evaluated for consistency, completeness, and accuracy and, in certain circumstances, further inquiries were made to clarify the responses; and

    •where further inquiry was needed, Penumbra reviewed information available from other public sources regarding the 3TG Minerals contained in a 3TG Supplier’s materials.

    Of the ten 3TG Suppliers, five confirmed via their CMRT and related documentation that the 3TG minerals contained in their materials supplied to the Company and contained in the Products were obtained from smelters that do not source 3TG Minerals from the Covered Countries. These 3TG Suppliers also confirmed via their CMRT that they had received responses to their supply chain survey from one hundred percent (100%) of the relevant smelters.

    Four 3TG Suppliers indicated via their CMRT that the Responsible Minerals Initiative (“RMI”) (formerly the Conflict-Free Sourcing Initiative) RCOI data suggested that it was possible that the tin, tungsten, and/or gold contained in their materials supplied to the Company and contained in the Products was sourced from the Covered Countries. Penumbra requested additional information from these 3TG Suppliers and reviewed publicly available information (including but not limited to the 3TG Suppliers’ conflict minerals policies and statements) to confirm the 3TG Suppliers’ commitment to conflict-free sourcing. Further, Penumbra reviewed information provided by RMI regarding the smelters described in the CMRTs that source tin,



    tungsten, and/or gold from the Covered Countries and that may have sourced the 3TG Minerals contained in the materials supplied to the Company by the 3TG Suppliers and contained in the Products, and confirmed whether these smelters are conformant with the Responsible Minerals Assurance Process (RMAP) standard for tin, tungsten, and/or gold, as applicable (commonly known as the Conflict-Free Smelter Program), which provides a mechanism through which 3TG Mineral smelters can certify their compliance with the Rule.

    One 3TG Supplier, which supplies materials containing tungsten for use in the Products, informed the Company that responses to their supply chain survey indicated that the 3TG Minerals contained in their materials supplied to the Company and contained in the Products were obtained from smelters that do not source 3TG Minerals from the Covered Countries, but that the 3TG Supplier had received responses to their supply chain survey from less than one hundred percent (100%) of the relevant smelters. Penumbra requested additional information from this 3TG Supplier and reviewed publicly available information (including but not limited to the 3TG Supplier’s Conflict Minerals Policy) to confirm the 3TG Supplier’s commitment to conflict-free sourcing.

    Based on responses received, the Company determined that 3TG Minerals present in certain of the Products may have originated in the Covered Countries and may not be from scrap or recycled sources. The Company has elected not to file disclosure under Item 1.01(c) of Form SD in accordance with the “Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule” issued by the Division of Corporation Finance of the Securities and Exchange Commission (the “SEC”) on April 7, 2017.

    This Form SD is publicly available at www.penumbrainc.com as well as the SEC’s website located at www.sec.gov. The content of any website referred to in this Form SD is included for general information only and is not incorporated by reference in this Form SD.
    Item 1.02. Exhibit

    None.

    Item 2.01. Exhibits

    None.
     








    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
      PENUMBRA, INC.
    Dated: May 30, 2025  By: /s/ Johanna Roberts
      Name: Johanna Roberts
      Title: Executive Vice President, General Counsel and Secretary


    Get the next $PEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    7/31/2024$289.00 → $150.00Overweight → Equal Weight
    Wells Fargo
    7/31/2024$165.00 → $178.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

      ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "

      7/1/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

      STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif., June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for the treatment of acute

      6/16/25 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

      ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. "We've engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings," said Shruthi Naraya

      6/5/25 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Penumbra with a new price target

      BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

      3/14/25 7:46:38 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Penumbra with a new price target

      UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00

      1/21/25 8:26:37 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Penumbra with a new price target

      Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00

      12/17/24 7:54:12 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Gen. Counsel & Secretary Roberts Johanna sold $151,622 worth of shares (600 units at $252.70), decreasing direct ownership by 0.90% to 66,057 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      7/3/25 7:54:20 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • EVP, Gen. Counsel & Secretary Roberts Johanna exercised 1,943 shares at a strike of $22.04, increasing direct ownership by 3% to 66,657 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      6/27/25 8:04:23 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $4,026,589 worth of shares (15,890 units at $253.40), increasing direct ownership by 11% to 122,441 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      6/27/25 8:02:38 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    SEC Filings

    See more
    • SEC Form SD filed by Penumbra Inc.

      SD - Penumbra Inc (0001321732) (Filer)

      5/30/25 4:20:01 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Penumbra Inc (0001321732) (Filer)

      5/30/25 4:13:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Penumbra Inc.

      144 - Penumbra Inc (0001321732) (Subject)

      5/15/25 4:03:13 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

      Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

      10/10/24 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

      SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

      10/24/22 8:30:00 AM ET
      $BLZE
      $GSIT
      $PEN
      Computer Software: Prepackaged Software
      Technology
      Semiconductors
      Medical/Dental Instruments

    $PEN
    Financials

    Live finance-specific insights

    See more
    • Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

      ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "

      7/1/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/14/24 1:22:36 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/12/24 12:53:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Penumbra Inc.

      SC 13G - Penumbra Inc (0001321732) (Subject)

      2/14/24 10:03:02 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care